FDA-cleared profile

MammoScreen® (5)

Therapixel · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Clinical role
Concurrent reading/reporting aid; includes an initial report populated with selected findings.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K260714 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for concurrent review of screening FFDM or DBT from systems compatible with this MammoScreen 5 record.

Limits to check

  • Physician interpretation remains required. Do not carry an older release's input rules into this release, or assume a separate density module is included.

Questions for the vendor and your team

  1. Which release, acquisition systems, prior-image scenarios and licensed reporting functions are covered by the quote?
  2. Can readers verify finding marks and the initial report against the original images, with an agreed correction and fallback workflow?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image interpretation · source-reviewed 2026-11-05

FDA K260714 summary, page 6: concurrent mammogram interpretation and reporting aid. This role does not establish local compatibility or autonomous diagnosis.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.
  • Who uses it?Intended users: Physicians interpreting screening mammograms.
  • What does the software produce?Output: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.
  • What is its most important limitation?Key limitation: Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.

Clinical takeaway. Clinical role: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Evidence takeaway. Evidence from the reviewed source record: New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K260714 · agent source review 2026-11-12 · exact submission

Existing study anchor: MammoScreen 5 standalone performance testing of newly introduced scenarios. Tested version label: MammoScreen 5.

What was tested?

MammoScreen 5 standalone testing evaluated newly introduced image/view and current/prior scenarios. Clinical documentation from MammoScreen 3 was carried forward; no additional clinical study was conducted for this submission.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

On which cases and versions?

The standalone table reports 9,789 patients/studies with biopsy and follow-up reference classifications. This is not a new 9,789-case version-5 reader trial. The admitted study anchor is MammoScreen 5 standalone testing of newly introduced scenarios; MammoScreen 3 K240301 clinical documentation is a separate carried-forward component.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

What changed?

The submission states that the algorithm did not change from MammoScreen 4 and reports scenario-level non-inferiority testing. Scenario differences include both positive and negative estimates; no single performance gain is assigned to all scenarios.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

What does this not establish?

Carryover evidence does not create a new version-5 clinical trial. Ambiguous extracted demographic totals are not converted to percentages. Exact input combinations, downstream recalls and clinical outcomes cannot be inferred from a combined score.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

Study design, population and missing context
evidence Role
Newly introduced scenario standalone evaluation, with clinical documentation carried forward from MammoScreen 3 K240301. These are separate evidence components.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

design
Standalone scenario comparisons for MammoScreen 5; no additional clinical studies conducted to support equivalence to MammoScreen 4.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Training/tuning and test data sources were separated; the reviewed table does not provide a complete training cohort description.

training · 510(k) summary, Non clinical Testing and Clinical Testing

evaluation Population
The standalone table reports 9,789 patients and 9,789 studies. Earlier MammoScreen 3 clinical-study documentation is cited separately.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

reference Standard
Positive cases biopsy-proven; benign cases use biopsy and/or imaging follow-up; negative cases verified by imaging follow-up as described in the table.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

comparator
New scenarios compared with reference scenarios previously supported by MammoScreen 4; algorithm described as unchanged from the predecessor.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM/DBT and prior-exam combinations, supplementary and duplicated views. Exact combination support must be read from the submission, not inferred across all vendors.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sample Composition
The table reports 9,789 studies. Extracted demographic category counts do not provide a consistent complete denominator; no percentages are computed here.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sponsor Involvement
Therapixel submitted the regulatory testing package and carryover clinical documentation. This does not establish independent investigator review.

regulatory summary · 510(k) summary, Non clinical Testing and Clinical Testing

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K260714 · agent source review 2026-11-09 · MammoScreen 5

Authorized population

Women undergoing mammography; the indication is screening mammography.

Label age limits

Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Documented care setting

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Modality and protocol

Screening mammograms from compatible FFDM and DBT systems; compatible prior examinations may also be used.

Acquisition constraints

Requires compatible full-field digital mammography or digital breast tomosynthesis systems; compatible priors are optional.

Exclusions and human review

Patient management decisions should not be made solely based on MammoScreen 5. The interpreting medical professional remains the sole decision-maker.

Purpose
Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Concurrent reading/reporting aid; includes an initial report populated with selected findings.
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Screening mammography workflow.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Physicians interpreting screening mammograms.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.
  • Exact FDA submission
  • Checked 2026-11-12

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-12
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No version-5 sensitivity value with complete endpoint context was abstracted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No version-5 specificity value with complete endpoint context was abstracted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MammoScreen 5 standalone performance testing of newly introduced scenarios

  • DesignStandalone non-inferiority comparison of newly introduced scenarios (supplementary views, duplicated views and current/prior combinations) with reference scenarios already cleared with MammoScreen 4.
  • Population9,789 patients and 9,789 studies from test-group data sources kept separate from training/tuning; positives biopsy-proven, benign cases verified by imaging follow-up (plus biopsy if biopsied), negatives verified by imaging follow-up.
  • Scopeexact submission
  • Tested versionMammoScreen 5
  • Samplen=9789
  • IndependenceIndependence not established

K260714

The submission states the algorithm did not change from MammoScreen 4 and no additional clinical studies were conducted; MammoScreen 3 (K240301) clinical study results are cited separately in the Clinical Testing section.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

GE FFDM/DBT input

Conditional support

  • AI version: MammoScreen 5; system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: FDA-labeled FFDM/DBT input from compatible GE equipment; a software build is not identified.
  • Condition: Confirm the precise acquisition model, software, priors and supported scenarios against the release-specific labeling.
  • Local test needed: Route representative labeled exams and verify study identity, findings, reporting and fallback review.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

Hologic FFDM/DBT input

Conditional support

  • AI version: MammoScreen 5; system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: FDA-labeled FFDM/DBT input from compatible Hologic equipment; a software build is not identified.
  • Condition: Confirm the precise acquisition model, software and current/prior image scenarios; do not extend the claim to every Hologic configuration.
  • Local test needed: Test the agreed inputs and exclusions, findings, initial report and retained physician review.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

Merge PACS

Not reviewed for this pairing

  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Merge describes mammography integrations including Therapixel. The source does not identify MammoScreen 5 and a specific Merge build.
  • Condition: A supplier-family integration statement is context, not qualification of this FDA record or site installation.
  • Local test needed: Obtain the two exact builds, licensed interface and conformance/acceptance evidence from both suppliers.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 9.5; Public technical document; reviewed 2026-11-06.
  • Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation.
  • The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

Existing route context (at most two)

Broader supplier context
  • Not reviewed for this pairing
  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Merge describes mammography integrations including Therapixel. The source does not identify MammoScreen 5 and a specific Merge build.
  • Condition: A supplier-family integration statement is context, not qualification of this FDA record or site installation.
  • Local test needed: Obtain the two exact builds, licensed interface and conformance/acceptance evidence from both suppliers.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 9.5; Public technical document; reviewed 2026-11-06.
  • Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation.
  • The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Merge PACS: AI integration and mammography context · Merge PACS 9.5 DICOM conformance statement · FDA Z-3004-2026: affected Merge 9.5 ultrasound measurements

Scanner/input support
  • Conditional support
  • AI version: MammoScreen 5; system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: FDA-labeled FFDM/DBT input from compatible GE equipment; a software build is not identified.
  • Condition: Confirm the precise acquisition model, software, priors and supported scenarios against the release-specific labeling.
  • Local test needed: Route representative labeled exams and verify study identity, findings, reporting and fallback review.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

MammoScreen 5: K260714 clearance and 510(k) summary

  1. Acquisition/source

    Source context, not route validation: Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.

    Scope: Product family. Current family documentation, not evidence that every interface or package shipped with the cleared version.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · MammoScreen integration

  3. AI processing

    Source context, not route validation: Current family documentation describes a site gateway with cloud computation and an on-premises option available on request.

    Scope: Product family.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · MammoScreen integration

  4. Returned objects

    Source context, not route validation: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Current family documentation describes a site gateway with cloud computation and an on-premises option available on request.
  • Product family
  • Checked 2026-09-06
Integration
Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.
  • Product family
  • Checked 2026-09-06

Current family documentation, not evidence that every interface or package shipped with the cleared version.

Security
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Training
The vendor offers a limited-time pilot with remote installation and training.
  • Product family
  • Checked 2026-09-06

Duration, curriculum and applicability to version 5 are not stated.

Family integration

DICOM Secondary Capture and Structured Report output; optional HL7/FHIR reporting integration.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260714
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

MammoScreen reading aid

Open the documented family

A partial mapping of MammoScreen 4 and 5 reading-aid records. Density products and other releases are not included in this mapping.

Therapixel identifies MammoScreen as its screening-mammography reading software. The manufacturer-prepared K260714 summary explicitly identifies K243679 as MammoScreen 4 and describes both as software versions of MammoScreen. This does not transfer tested input scenarios, evidence, licenses or availability between records.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. Related FDA recordMammoScreen® (4) (K243679)

    MammoScreen 4 reviewed in K243679

    FDA decision: 2025-07-03 · record reviewed 2026-11-05
  2. This FDA recordMammoScreen® (5) (K260714)

    MammoScreen 5 reviewed in K260714

    Latest mapped FDA decisionFDA decision: 2026-06-26 · record reviewed 2026-11-05
Latest FDA decision among these records
K260714 · 2026-06-26. Latest decision among these mapped records only. This is not a current installed-version or supersession claim.
Latest documented release
The sources do not establish a complete current commercial release chronology.
Current commercial availability
Availability of an exact release and licensed configuration must be confirmed with the supplier.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
20Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PMID 32159424 is an online breast-cancer risk decision-aid study, not MammoScreen product evidence; excluded by metadata. No trial records stored. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor product page, vendor technical page, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact product version

    No public price or contract for MammoScreen 5 was located in the reviewed vendor material.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-06 - Exact product version

    No site monitoring or update-acceptance procedure was established.

13 sources - 3 history items

Source ledger

  1. K260714 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MammoScreen® (5) model card (K260714)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. MammoScreen 5: K260714 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence, product_family

  8. MammoScreen integration

    Therapixel / MammoScreen - Accessed 2026-09-06

    Scope: product_family_implementation

  9. Try MammoScreen

    Therapixel / MammoScreen - Accessed 2026-09-06

    Scope: product_family_training

  10. MammoScreen 4: K243679 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  11. Therapixel is now ISO/IEC 27001 certified

    Therapixel - Accessed 2026-10-25

    Scope: security

  12. MammoScreen by Therapixel: product identity

    Therapixel / MammoScreen - Accessed 2026-11-05

    Scope: product_family

  13. Merge PACS: AI integration and mammography context

    Merge - Accessed 2026-11-06

    Scope: product_family_implementation

Research history

  1. K260714 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history